Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Chronic kidney disease may not be deterrent for B-FEVAR

Key clinical point: Endovascular aortic aneurysm repair was performed safely in well-selected patients with renal dysfunction.

Major finding: Thirty-day mortality was 1.35% in Stage I to III kidney disease, similar to more advanced disease.

Study details: Single-institution retrospective review of prospectively collected data of 231 patients from 2013 to 2017.

Disclosures: Dr. Cajas-Monson has no financial relationships to disclose.

Citation:

Cajas-Monson LC et al. Midwestern Vascular 2019, Abstract 19.